Lantheus Holdings, Inc.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
LNTH$101.62+0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Cash flows from operating activities: | |||
| Net income | $233,559 | $312,442 | $326,661 |
| Adjustments to reconcile net income to net cash flows from operating activities: | |||
| Depreciation, amortization and accretion | 70,098 | 64,624 | 60,043 |
| Impairment of long-lived assets | — | — | 138,050 |
| Adjustment to the fair value of asset retirement obligation | (4,727) | — | — |
| Amortization of debt-related costs | 4,457 | 4,296 | 4,300 |
| Change in fair value of contingent liabilities | 1,379 | (2,699) | (9,275) |
| Inventory adjustments | 2,202 | (904) | 7,914 |
| Stock-based compensation | 85,563 | 76,393 | 50,507 |
| Gain on disposal of assets | — | (8,415) | — |
| Gain on sale of RELISTOR licensed intangible asset | (5,000) | — | (51,789) |
| Unrealized loss on investment in equity securities | 8,617 | 43,564 | — |
| Charges incurred pursuant to acquired in-process research and development | 11,212 | 66,000 | — |
| Deferred taxes | 21,595 | (30,029) | (55,632) |
| Long-term indemnification receivable | — | — | 3,929 |
| Long-term income tax payable and other long-term liabilities | 246 | 5,236 | (3,103) |
| Other, net | 5,174 | 12,194 | 4,855 |
| Changes in operating assets and liabilities, excluding impact of acquisitions: | |||
| Accounts receivable | (17,888) | (37,685) | (68,637) |
| Inventory | (9,366) | (2,670) | (36,220) |
| Other current and noncurrent assets | (5,406) | 4,440 | (2,418) |
| Accounts payable | (2,492) | (8,804) | 17,189 |
| Accrued expenses and other current and long-term liabilities | (9,082) | 46,767 | (81,114) |
| Net cash provided by operating activities | 390,141 | 544,750 | 305,260 |
| Cash flows from investing activities: | |||
| Capital expenditures | (36,089) | (51,625) | (46,555) |
| Acquisition of in-process research and development | (5,413) | — | — |
| Proceeds from sale of assets | — | 17,767 | 97,839 |
| Acquisition of assets, net | — | (80,911) | (45,345) |
| Acquisition of Evergreen, net of cash acquired | (268,933) | — | — |
| Acquisition of Life Molecular, net of cash acquired | (306,733) | — | — |
| Purchases of investment in equity securities | (10,000) | (83,246) | — |
| Acquisition of exclusive license option | — | (28,000) | — |
| Net cash (used in) provided by investing activities | (627,168) | (226,015) | 5,939 |
| Cash flows from financing activities: | |||
| Payments of long-term debt and other borrowings | (1,110) | (318) | (717) |
| Deferred financing costs | — | (2,331) | — |
| Proceeds from stock option exercises | 7,154 | 3,278 | 3,816 |
| Contingent value rights settlement | — | — | (3,700) |
| Proceeds from employee stock purchase plan | 3,727 | 3,450 | 1,933 |
| Payments for minimum statutory tax withholding related to net share settlement of equity awards | (26,338) | (22,615) | (14,394) |
| Repurchase of common stock | (300,017) | (100,000) | — |
| Net cash used in financing activities | (316,584) | (118,536) | (13,062) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (49) | (998) | (93) |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (553,660) | 199,201 | 298,044 |
| Cash, cash equivalents and restricted cash, beginning of period | 914,486 | 715,285 | 417,241 |
| Cash, cash equivalents and restricted cash, end of period | $360,826 | $914,486 | $715,285 |
Consolidated Statements of Cash Flows (Continued)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Reconciliation to amounts within the consolidated balance sheets | |||
| Cash and cash equivalents | $359,121 | $912,814 | $713,656 |
| Restricted cash included in other long-term assets | 1,705 | 1,672 | 1,629 |
| Cash, cash equivalents and restricted cash at end of period | $360,826 | $914,486 | $715,285 |
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Supplemental disclosure of cash flow information | |||
| Cash paid during the period for: | |||
| Interest | $15,094 | $15,094 | $15,387 |
| Income taxes , net of refunds of $28, $2,688 and $25, respectively | $69,037 | $153,815 | $151,579 |
| Schedule of non-cash investing and financing activities | |||
| Additions of property, plant and equipment included in liabilities | $3,445 | $5,058 | $6,978 |
| In-process research and development included in liabilities | $5,799 | $— | $— |
| Contingent consideration liabilities related to acquisitions | $96,842 | $— | $— |
| Lease liability settled through transfer of lease | $— | $762 | $— |
| Modification of lease agreement | $5,789 | $— | $— |
| Right-of-use asset obtained in exchange for operating lease liabilities | $2,770 | $63 | $29,396 |
| Right-of-use asset obtained in exchange for finance lease obligation | $711 | $514 | $1,581 |
| Excise tax payable on net common stock repurchases | $2,421 | $251 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.